Abstract
Dermatofibrosarcoma protuberans (DFSP) is a rare soft tissue neoplasm arising from mesenchymal cells, making up about 6% of all soft tissue tumours1. The most commonly involved sites are the trunk (42–72%) and proximal extremities (16–30%)2. It generally has intermediate- to low-grade malignancy potential with the exception of the fibrosarcomatous variant (high-grade). This variant is more likely to metastasise (in less than 5% of cases) to the lungs and lymph nodes and may occur many years after the onset of disease3. Herein, we present the case of a 40-yearold male who presented with a two-month history of a lump in the upper abdomen with pressure symptoms and past history of recurrent dermatofibrosarcoma of the left shoulder. Computed tomography (CT) revealed a mass arising from the greater curvature of the stomach. The patient underwent exploratory laparotomy which revealed a tumour mass arising from the retroperitoneum The mass was resected and sent for histopathology which revealed a fibrosarcomatous variant of dermatofibrosarcoma protuberans (FS-DFSP).
Similar content being viewed by others
References
Kransdorf MJ. Malignant soft-tissue tumors in a large referral population: distribution of diagnoses by age, sex, and location. AJR Am J Roentgenol 1995;164:129–34.
Lemm D, Mugge LO, Mentzel T, et al. Current treatment options in dermatofibrosarcoma protuberans. J Cancer Res Clin Oncol 2009; 135:653–65.
Ammad Al-Tamimi, Sumbul Zaheer, Kesavan Sittampalam et al. Recurrent Dermatofibrosarcoma Protuberans of the Shoulder with Rare Distant Abdominal Metastasis detected by Fluorodeoxyglucose-Positron Emission Tomography/ Computed Tomography (FDG-PET/CT). Sultan Qaboos Univ Med J 2012; 12:371–4.
Kim GK. Status report on the management of dermatofibrosarcoma protuberans: is there a viable role for the use of imatinib mesylate? In which cases may it be therapeutically helpful and in which cases not? J Clin Aesthet Dermatol 2011;4:17–26.
Weiss SW and Nickoloff BJ. CD-34 is expressed by a distinctive cell population in peripheral nerve, nerve sheath tumors, and related lesions. Am J Surg Pathol 1993;17:1039–45.
Haycox CL, Odland PB, Olbricht SM, Piepkorn M. Immunohistochemical characterization of dermatofibrosarcoma protuberans with practical applications for diagnosis and treatment. J Am Acad Dermatol 1997; 37:438–44.
Naeem R, Lux ML, Huang SF, et al. Ring chromosomes in dermatofibrosarcoma protuberans are composed of interspersed sequences from chromosomes 17 and 22. Am J Pathol 1995; 147:1553–8.
O'Brien KP, Seroussi E, Dal Cin P. Various regions within the alpha-helical domain of the COL1A1 gene are fused to the second exon of the PDGFB gene in dermatofibrosarcomas and giant-cell fibroblastomas. Genes Chromosomes Cancer 1998; 23:187–93.
Sirvent N, Maire G, Pedeutour F. Genetics of dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment. Genes Chromosomes Cancer 2003; 37:1–19.
Simon MP, Pedeutour F, Sirvent N. Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat Genet 1997; 15:95–8.
Mentzel T, Beham A, Katenkamp D, Dei Tos AP, Fletcher CDM. Fibrosarcomatous (“high-grade”) dermatofibrosarcoma protuberans: clinicopathologic and immunohistochemical study of a series of 41 cases with emphasis on prognostic significance. Am J Surg Pathol 1998; 22:576–87.
Wrotnowski U, Cooper PH, Shmookler BJ. Fibrosarcomatous change in dermatofibrosarcoma protuberans. Am J Surg Pathol 1998; 12:287–93.
Lindner NJ, Scarborough MT, Powell GJ, et al., Revision surgery in dermatofibrosarcoma protuberans of the trunk and extremities. Eur J Surg Oncol 1999; 25:392–7.
Brabant B, Revol M, Vergote T, Servant JM, Banzet P. Dermatofibrosarcoma protuberans of the chest and the shoulder: wide and deep excisions with immediate reconstruction. Plast Reconstr Surg 1993; 92:459–62.
Roses DF, Valensi Q, LaTrenta G, Harris MN. Surgical treatment of dermatofibrosarcoma protuberans. Surg Gynecol Obstet 1986;162:449–52.
Sun LM, Wang CJ, Huang CC. Dermatofibrosarcoma protuberans: treatment results of 35 cases. Radiother Oncol 2000; 57:175–81.
Dagan R, Morris CG, Zlotecki RA, Scarborough MT, Mendenhall WM. Radiotherapy in the treatment of dermatofibrosarcoma protuberans. Am J Clin Oncol 2005; 28:537–9.
McArthur GA. Dermatofibrosarcoma protuberans: a surgical disease with a molecular savior. Curr Opin Oncol 2006; 18:341–6.
Han A, Chen E, Niedt G, Sherman W, Ratner D. Neoadjuvant imatinib therapy for dermatofibrosarcoma protuberans. Arch Derm 2009; 145:792–6.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gupta, N., Gupta, A.K., Krishnegowda, U. et al. Fibrosarcomatous dermatofibrosarcoma metastasizing to retroperitoneum four years after resection of primary lesion - A case report with review of literature. Hellenic J Surg 87, 505–508 (2015). https://doi.org/10.1007/s13126-015-0270-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13126-015-0270-x